Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$139M in Q4 2025 → $207M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Kyverna Therapeutics Inc | 18.3% | Unchanged | 4,244,818 | $37.8M |
| Pyxis Oncology Inc | 14.6% | Added 143% | 10,024,909 | $30.2M |
| Taysha Gene Therapies Inc | 11.9% | Trimmed 1.9% | 723,185 | $24.5M |
| TP Teva Pharmaceutical Inds Ltd | 7.9% | Added 91% | 2,402,495 | $16.4M |
| Vir Biotechnology Inc | 6.7% | Trimmed 11% | 1,353,552 | $13.8M |
| Allogene Therapeutics Inc | 5.3% | Added 270% | 5,298,000 | $11M |
| CT Celldex Therapeutics Inc New | 5.0% | Added 64% | 279,720 | $10.4M |
| Editas Medicine Inc | 4.9% | New | 3,127,000 | $10.1M |
| UP Ultragenyx Pharmaceutical In | 4.7% | Unchanged | 289,101 | $9.65M |
| BP Bausch Plus Lomb Corp | 4.6% | Unchanged | 573,472 | $9.5M |
| Amgen Inc | 3.5% | Unchanged | 20,212 | $7.32M |
| SR Scholar Rock Hldg Corp | 3.5% | Unchanged | 132,500 | $7.29M |
| Sionna Therapeutics Inc | 2.9% | Unchanged | 136,000 | $5.98M |
| Incyte Corp | 2.4% | Unchanged | 43,300 | $4.91M |
| CP Crinetics Pharmaceuticals In | 2.3% | Unchanged | 126,985 | $4.75M |
| Insmed Inc | 1.5% | Unchanged | 28,587 | $3.05M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pyxis Oncology Inc | Added | +5,903,039 | +$17.8M | 14.6% |
| Editas Medicine Inc | New | +3,127,000 | +$10.1M | 4.9% |
| Allogene Therapeutics Inc | Added | +3,868,000 | +$8.05M | 5.3% |
| TP Teva Pharmaceutical Inds Ltd | Added | +1,145,000 | +$7.8M | 7.9% |
| CT Celldex Therapeutics Inc New | Added | +109,413 | +$4.07M | 5.0% |
| Tarsus Pharmaceuticals Inc | Exited | −42,680 | −$2.99M | — |
| Vir Biotechnology Inc | Trimmed | −165,000 | −$1.68M | 6.7% |
| Taysha Gene Therapies Inc | Trimmed | −14,365 | −$487K | 11.9% |
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Taysha Gene Therapies Inc | Trimmed | −593,351 | −$17.9M | 15.5% |
| SR Scholar Rock Hldg Corp | New | +132,500 | +$6.51M | 4.5% |
| Sionna Therapeutics Inc | New | +136,000 | +$5.45M | 3.8% |
| Vir Biotechnology Inc | Added | +588,235 | +$5.27M | 9.5% |
| CP Crinetics Pharmaceuticals In | Trimmed | −97,150 | −$3.53M | 3.2% |
| Allogene Therapeutics Inc | New | +1,430,000 | +$3.49M | 2.4% |
| TP Teva Pharmaceutical Inds Ltd | Added | +487,945 | +$2.18M | 3.9% |
| Tarsus Pharmaceuticals Inc | Trimmed | −24,000 | −$1.68M | 2.1% |
| Kyverna Therapeutics Inc | Trimmed | −147,000 | −$1.27M | 25.5% |
| Amgen Inc | Trimmed | −3,000 | −$1.06M | 5.0% |
Showing the 10 largest of 13 changes.
Loading...
